Current strategies for managing intestinal failure-associated liver disease

References

• Andorsky DJ, Lund DP, Lillehei CW, et al. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr. 2001;139:27–33.
   PubMed Web of Science ®Google Scholar
• Lauriti G, Zani A, Aufieri R, et al. Incidence, prevention, and treatment of parenteral nutrition-associated cholestasis and intestinal failure-associated liver disease in infants and children: a systematic review. JPEN J Parenter Enteral Nutr. 2014 Jan;38(1):70–85.
   PubMed Web of Science ®Google Scholar
• Christensen RD, Henry E, Wiedmeier SE, et al. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J Perinatol. 2007;27:284–290.
   PubMed Web of Science ®Google Scholar
• Javid PJ, Collier S, Richardson D, et al. The role of enteral nutrition in the reversal of parenteral nutrition-associated liver dysfunction in infants. J Pediatr Surg. 2005 Jun;40(6):1015–1018.
   PubMed Web of Science ®Google Scholar
• Luman W, Shaffer JL. Prevalence, outcome and associated factors of deranged liver function tests in patients on home parenteral nutrition. Clin Nutr. 2002 Aug;21(4):337–343.
   PubMed Web of Science ®Google Scholar
• Pichler J, Horn V, Macdonald S, et al. Intestinal failure-associated liver disease in hospitalised children. Arch Dis Child. 2012 March;97(3):211–214.
   PubMed Web of Science ®Google Scholar
• Bond A, Huijbers A, Pironi L, et al. Review article: diagnosis and management of intestinal failure-associated liver disease in adults. Aliment Pharmacol Ther. 2019 Sep;50(6):640–653.
   PubMed Web of Science ®Google Scholar
• Roma MG, Toledo FD, Boaglio AC, et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond). 2011;121(12):523–544.
   PubMed Web of Science ®Google Scholar
• Duerksen DR, Van Aerde JE, Gramlich L, et al. Intravenous ursodeoxycholic acid reduces cholestasis in parenterally fed newborn piglets. Gastroenterology. 1996;111(4):1111–1117.
   PubMed Web of Science ®Google Scholar
• Gunsar C, Melek M, Karaca I, et al. The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Hepatogastroenterology. 2002;49(44):497–500.
   PubMedGoogle Scholar
• San Luis VA, Btaiche IF. Ursodiol in patients with parenteral nutrition-associated cholestasis. Ann Pharmacother. 2007;41(11):1867–1872.
   PubMed Web of Science ®Google Scholar
• Heemskerk J, Sie GH, Van den Neucker AM, et al. Extreme short bowel syndrome in a full-term neonate–a case report. J Pediatr Surg. 2003;38(11):1665–1666.
   PubMed Web of Science ®Google Scholar
• Beau P, Labat-Labourdette J, Ingrand P, et al. Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? J Hepatol. 1994;20(2):240–244.
   PubMed Web of Science ®Google Scholar
• Spagnuolo MI, Iorio R, Vegnente A, et al. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology. 1996;111(3):716–719.
   PubMed Web of Science ®Google Scholar
• Arslanoglu S, Moro GE, Tauschel HD, et al. Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. J Pediatr Gastroenterol Nutr. 2008;46(2):228–231.
   PubMed Web of Science ®Google Scholar
• Gokmen T, Oguz SS, Bozdag S, et al. A controlled trial of erythromycin and UDCA in premature infants during parenteral nutrition in minimizing feeding intolerance and liver function abnormalities. J Perinatol. 2012;32(2):123–128.
   PubMed Web of Science ®Google Scholar
• Stiehl A, Raedsch R, Rudolph G. Ileal excretion of bile acids: comparison with biliary bile composition and effect of ursodeoxycholic acid treatment. Gastroenterology. 1988;94(5 Pt 1):1201–1206.
   PubMed Web of Science ®Google Scholar
• Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med. 1975;82(3):310–317.
   PubMed Web of Science ®Google Scholar
• Wagner M, Halilbasic E, Marschall HU, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology. 2005;42(2):420–430.
   PubMed Web of Science ®Google Scholar
• Beilke LD, Aleksunes LM, Holland RD, et al. Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab Dispos. 2009;37(5):1035–1045.
   PubMed Web of Science ®Google Scholar
• Beilke LD, Aleksunes LM, Olson ER, et al. Decreased apoptosis during CAR-mediated hepatoprotection against lithocholic acid-induced liver injury in mice. Toxicol Lett. 2009;188(1):38–44.
   PubMed Web of Science ®Google Scholar
• South M, King A. Parenteral nutrition-associated cholestasis: recovery following phenobarbitone. JPEN J Parenter Enteral Nutr. 1987;11(2):208–209.
   PubMed Web of Science ®Google Scholar
• Gleghorn EE, Merritt RJ, Subramanian N, et al. Phenobarbital does not prevent total parenteral nutrition-associated cholestasis in noninfected neonates. JPEN J Parenter Enteral Nutr. 1986;10(3):282–283.
   PubMed Web of Science ®Google Scholar
• Lambert JR, Thomas SM. Metronidazole prevention of serum liver enzyme abnormalities during total parenteral nutrition. JPEN J Parenter Enteral Nutr. 1985;9(4):501–503.
   PubMed Web of Science ®Google Scholar
• Kaushal S, Tamer Z, Opoku F, et al. Anticonvulsant drug-induced cell death in the developing white matter of the rodent brain. Epilepsia. 2016;57(5):727–734.
   PubMed Web of Science ®Google Scholar
• Gutherz SB, Kulick CV, Soper C, et al. Brief postnatal exposure to phenobarbital impairs passive avoidance learning and sensorimotor gating in rats. Epilepsy Behav. 2014;37:265–269.
   PubMed Web of Science ®Google Scholar
• Freund HR, Muggia-Sullam M, LaFrance R, et al. A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements. J Surg Res. 1985;38(4):356–363.
   PubMed Web of Science ®Google Scholar
• Capron JP, Gineston JL, Herve MA, et al. Metronidazole in prevention of cholestasis associated with total parenteral nutrition. Lancet. 1983;1(8322):446–447.
   PubMed Web of Science ®Google Scholar
• Fleming CR. Hepatobiliary complications in adults receiving nutrition support. Dig Dis. 1994;12(4):191–198.
   PubMed Web of Science ®Google Scholar
• Rangel SJ, Calkins CM, Cowles RA, et al. Parenteral nutrition-associated cholestasis: an American pediatric surgical association outcomes and clinical trials committee systematic review. J Pediatr Surg. 2012;47(1):225–240.
   PubMed Web of Science ®Google Scholar
• Teitelbaum DH, Tracy TF Jr, Aouthmany MM, et al. Use of cholecystokinin-octapeptide for the prevention of parenteral nutrition-associated cholestasis. Pediatrics. 2005 May;115(5):1332–1340.
   PubMed Web of Science ®Google Scholar
• Mirtallo JM, Ayers P, Boullata J, et al. ASPEN lipid injectable emulsion safety recommendations, part 1: background and adult considerations. Nutr Clin Pract. 2020 Oct;35(5):769–782.
   PubMed Web of Science ®Google Scholar
• Alwayn IP, Gura K, Nosé V, et al. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar;57(3):445–452.
   PubMed Web of Science ®Google Scholar
• Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132:525–532.
   PubMed Web of Science ®Google Scholar
• Cober MP, Teitelbaum DH. Prevention of parenteral nutrition-associated liver disease: lipid minimization. Curr Opin Organ Transplant. 2010 Jun;15(3):330–333.
   PubMed Web of Science ®Google Scholar
• Colomb V, Jobert-Giraud A, Lacaille F, et al. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr. 2000;24(6):345–350.
   PubMed Web of Science ®Google Scholar
• Innis SM. Omega-3 Fatty acids and neural development to 2 years of age: do we know enough for dietary recommendations? J Pediatr Gastroenterol Nutr. 2009;48(Suppl 1):S16–S24.
   PubMedGoogle Scholar
• Nehra D, Fallon EM, Carlson SJ, et al. Provision of a soy-based intravenous lipid emulsion at 1 g/kg/d does not prevent cholestasis in neonates. JPEN J Parenter Enteral Nutr. 2013;37(4):498–505.
   PubMed Web of Science ®Google Scholar
• Rollins MD, Ward RM, Jackson WD, et al. Effect of decreased parenteral soybean lipid emulsion on hepatic function in infants at risk for parenteral nutrition-associated liver disease: a pilot study. J Pediatr Surg. 2013;48(6):1348–1356.
   PubMed Web of Science ®Google Scholar
• Sanchez SE, Braun LP, Mercer LD, et al. The effect of lipid restriction on the prevention of parenteral nutrition-associated cholestasis in surgical infants. J Pediatr Surg. 2013;48(3):573–578.
   PubMed Web of Science ®Google Scholar
• Blackmer AB, Warschausky S, Siddiqui S, et al. Preliminary findings of long-term neurodevelopmental outcomes of infants treated with intravenous fat emulsion reduction for the management of parenteral nutrition-associated cholestasis. JPEN J Parenter Enteral Nutr. 2015;39(1):34–46.
   PubMed Web of Science ®Google Scholar
• Levit OL, Calkins KL, Gibson LC, et al. Low-dose intravenous soybean oil emulsion for prevention of cholestasis in preterm neonates. JPEN J Parenter Enteral Nutr. 2016;40(3):374–382.
   PubMed Web of Science ®Google Scholar
• Calkins KL, Havranek T, Kelley-Quon LI, et al. Low-dose parenteral soybean oil for the prevention of parenteral nutrition-associated liver disease in neonates with gastrointestinal disorders. JPEN J Parenter Enteral Nutr. 2017;41(3):404–411.
   PubMed Web of Science ®Google Scholar
• de Meijer VE, Gura KM, Le HD, et al. Puder M Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr. 2009 Sep-Oct;33(5):541–547.
   PubMed Web of Science ®Google Scholar
• Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oil-based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics. 2008;121:e678–e686.
   PubMed Web of Science ®Google Scholar
• Gura KM, Duggan CP, Collier SB, et al. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics. 2006;118(1):e197–e201.
   PubMed Web of Science ®Google Scholar
• Puder M, Valim C, Meisel JA, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009;250(3):395–402.
   PubMed Web of Science ®Google Scholar
• Premkumar MH, Carter BA, Hawthorne KM, et al. High rates of resolution of cholestasis in parenteral nutrition-associated liver disease with fish oil-based lipid emulsion monotherapy. J Pediatr. 2013;162(4):793–798.e1.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Hernandez J, Prajapati P, Ogola G, et al. A comparison of lipid minimization strategies in children with intestinal failure. J Pediatr Surg. 2017;S0022-3468(17):30652–30658.
   Google Scholar
• Gura K, Premkumar MH, Calkins KL, et al., Intravenous fish oil monotherapy as a source of calories and fatty acids promotes age-appropriate growth in pediatric patients with intestinal failure-associated liver disease. e4. J Pediatr 2020 April;219:98–105.
   PubMed Web of Science ®Google Scholar
• Lam HS, Tam YH, Poon TC, et al. A double-blind randomised controlled trial of fish oil-based versus soy-based lipid preparations in the treatment of infants with parenteral nutrition-associated cholestasis. Neonatology. 2014;105(4):290–296.
   PubMed Web of Science ®Google Scholar
• Wang C, Venick RS, Shew SB, et al. Long‐term outcomes in children with intestinal failure‐associated liver disease treated with 6 months of intravenous fish oil followed by resumption of intravenous soybean oil. JPEN J Parenter Enteral Nutr. 2019;43(6):708‐716.
   Web of Science ®Google Scholar
• Strijbosch RA, Lee S, Arsenault DA, et al. Fish oil prevents essential fatty acid deficiency and enhances growth: clinical and biochemical implications. Metabolism. 2008;57(5):698‐707.
   PubMed Web of Science ®Google Scholar
• Nandivada P, Anez-Bustillos L, O’Loughlin AA, et al. Risk of post-procedural bleeding in children on intravenous fish oil. Am J Surg. 2017 Oct;214(4):733–737.
   PubMed Web of Science ®Google Scholar
• Nandivada P, Baker MA, Mitchell PD, et al. Predictors of failure of fish-oil therapy for intestinal failure-associated liver disease in children. Am J Clin Nutr. 2016 September;104(3):663–667.
   PubMed Web of Science ®Google Scholar
• Diamond IR, Sterescu A, Pencharz PB, et al. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009 Feb;48(2):209–215.
   PubMed Web of Science ®Google Scholar
• Sala-Vila A, Barbosa VM, Calder PC. Olive oil in parenteral nutrition. Curr Opin Clin Nutr Metab Care. 2007;10:165–174.
   PubMed Web of Science ®Google Scholar
• Webb AN, Hardy P, Peterkin M, et al. Tolerability and safety of olive oil-based lipid emulsion in critically ill neonates: a blinded randomized trial. Nutrition. 2008;24:1057–1064.
   PubMed Web of Science ®Google Scholar
• Angsten G, Finkel Y, Lucas S, et al. Improved outcome in neonatal short bowel syndrome using parenteral fish oil in combination with ω-6/9 lipid emulsions. JPEN J Parenter Enteral Nutr. 2012 Sep;36(5):587–595.
   PubMed Web of Science ®Google Scholar
• Goulet O, Antébi H, Wolf C, et al. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010;34(5):485–495.
   PubMed Web of Science ®Google Scholar
• Tomsits E, Pataki M, Tölgyesi A, et al. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J Pediatr Gastroenterol Nutr. 2010;51(4):514–521.
   PubMed Web of Science ®Google Scholar
• Muhammed R, Bremner R, Protheroe S, et al. Resolution of parenteral nutrition-associated jaundice on changing from a soybean oil emulsion to a complex mixed-lipid emulsion. J Pediatr Gastroenterol Nutr. 2012;54(6):797–802.
   PubMed Web of Science ®Google Scholar
• Diamond IR, Grant RC, Pencharz PB, et al. Preventing the progression of intestinal failure-associated liver disease in infants using a composite lipid emulsion: a pilot randomized controlled trial of SMOflipid. JPEN J Parenter Enteral Nutr. 2017;41(5):866–877.
   PubMed Web of Science ®Google Scholar
• Lam CKL, Church PC, Haliburton B, et al. Long-term exposure of children to a mixed lipid emulsion is less hepatotoxic than soybean-based lipid emulsion. J Pediatr Gastroenterol Nutr. 2018;66(3):501–504.
   PubMed Web of Science ®Google Scholar
• Carey AN, Rudie C, Mitchell PD, et al. Essential fatty acid status in surgical infants receiving parenteral nutrition with a composite lipid emulsion: a case series. JPEN J Parenter Enteral Nutr. 2019 Feb;43(2):305–310.
   PubMed Web of Science ®Google Scholar
• Repa A, Binder C, Thanhaeuser M, et al. A mixed lipid emulsion for prevention of parenteral nutrition associated cholestasis in extremely low birth weight infants: a randomized clinical trial. J Pediatr. 2018 Mar;194(87–93) . e1.
   PubMed Web of Science ®Google Scholar
• Wu GH, Gao J, Ji CY, Pradelli L, Xi QL, Zhuang QL. Cost and effectiveness of omega-3 fatty acid supplementation in Chinese ICU patients receiving parenteral nutrition. Clinicoecon Outcomes Res. 2015;7:369–375.
   PubMed Web of Science ®Google Scholar
• Pradelli L, Muscaritoli M, Klek S, Martindale RG. Pharmacoeconomics of parenteral nutrition with omega-3 fatty acids in hospitalized adults. JPEN J Parenter Enteral Nutr. 2020;44(Suppl 1):S68–S73.
   PubMedGoogle Scholar
• Dodge ME, Bertolo RF, Brunton JA. Enteral feeding induces early intestinal adaptation in a parenterally fed neonatal piglet model of short bowel syndrome. JPEN J Parenter Enteral Nutr. 2012;36(2):205–212.
   PubMed Web of Science ®Google Scholar
• Shores DR, Alaish SM, Aucott SW, et al. Postoperative enteral nutrition guidelines reduce the risk of intestinal failure–associated liver disease in surgical infants. J Pediatr. 2018 e1;195:140–147.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Mercado V, Rios M, et al. Breast milk is better than formula milk in preventing parenteral nutrition–associated liver disease in infants receiving prolonged parenteral nutrition. J Pediatr Gastroenterol Nutr. 2013;57(3):383–388.
   PubMed Web of Science ®Google Scholar
• Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143:1473–1481.
   PubMed Web of Science ®Google Scholar
• Quirós-Tejeira RE, Ament ME, Reyen L, et al. Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: A 25-year experience. J Pediatr. 2004;145(2):157–163.
   PubMed Web of Science ®Google Scholar
• Adaba F, Uppara M, Iqbal F, et al. Chronic cholestasis in patients on parenteral nutrition: the influence of restoring bowel continuity after mesenteric infarction. Eur J Clin Nutr. 2016 Feb;70(2):189–193.
   PubMed Web of Science ®Google Scholar
• Li S, Nussbaum MS, Teague D, et al. Increasing dextrose concentrations in total parenteral nutrition (TPN) causes alterations in hepatic morphology and plasma levels of insulin and glucagon in rats. J Surg Res. 1988;44(6):639–648.
   PubMed Web of Science ®Google Scholar
• Vileisis RA, Inwood RJ, Hunt CE. Prospective controlled study of parenteral nutrition-associated cholestatic jaundice: effect of protein intake. J Pediatr. 1980 May;96(5):893–897.
   PubMed Web of Science ®Google Scholar
• Roth B, Ekelund M, Fan BG, et al. Biochemical and ultra-structural reactions to parenteral nutrition with two different fat emulsions in rats. Intensive Care Med. 2013;24(7):716.
   Google Scholar
• Cober MP, Killu G, Brattain A, et al. Intravenous fat emulsions reduction for patients with parenteral nutrition–associated liver disease. J Pediatr. 2012;160(3):421–427.
   PubMed Web of Science ®Google Scholar
• Moss RL, Haynes AL, Pastuszyn A, et al. Methionine infusion reproduces liver injury of parenteral nutrition cholestasis. Pediatr Res. 1999;45(Suppl 5):664–668.
   PubMed Web of Science ®Google Scholar
• Fell GL, Anez-Bustillos L, Dao DT, et al. Alpha-tocopherol in intravenous lipid emulsions imparts hepatic protection in a murine model of hepatosteatosis induced by the enteral administration of a parenteral nutrition solution. PloS One. 2019;14(7):e0217155.
   PubMed Web of Science ®Google Scholar
• Ng K, Stoll B, Chacko S, et al. Vitamin E in new-generation lipid emulsions protects against parenteral nutrition-associated liver disease in parenteral nutrition-fed preterm pigs. JPEN J Parenter Enteral Nutr. 2015;40(5):656–671.
   PubMed Web of Science ®Google Scholar
• Muto M, Lim D, Soukvilay A, et al. Supplemental parenteral vitamin e into conventional soybean lipid emulsion does not prevent parenteral nutrition-associated liver disease in full-term neonatal piglets. JPEN J Parenter Enteral Nutr. 2015;41(4):575–582.
   PubMed Web of Science ®Google Scholar
• Buchman AL. Choline deficiency during parenteral nutrition in humans. Nutr Clin Pract. 2003 Oct;18(5):353–358.
   PubMedGoogle Scholar
• Protara therapeutics receives fast track designation from U.S. FDA for intravenous choline chloride for the treatment of intestinal failure associated liver disease. https://www.globenewswire.com/news-release/2020/05/26/2038632/0/en/Protara-Therapeutics-Receives-Fast-Track-Designation-from-U-S-FDA-for-Intravenous-Choline-Chloride-for-the-Treatment-of-Intestinal-Failure-Associated-Liver-Disease.html [ accessed 2020 9 13].
   Google Scholar
• Kasmi KCE, Anderson AL, Devereaux MW, et al. Phytosterols promote liver injury and kupffer cell activation in parenteral nutrition-associated liver disease. Sci Transl Med. 2013;5(206):206ra137–206ra137.
   PubMed Web of Science ®Google Scholar
• Carter BA, Taylor OA, Prendergast DR, et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res. 2007 Sep;62(3):301–306.
   PubMed Web of Science ®Google Scholar
• Mutanen A, Nissinen MJ, Lohi J, et al. Serum plant sterols, cholestanol, and cholesterol precursors associate with histological liver injury in pediatric onset intestinal failure. Am J Clin Nutr. 2014;100(4):1085–1094.
   PubMed Web of Science ®Google Scholar
• Klein GL, Heyman MB, Lee TC, et al. Aluminum-associated hepatobiliary dysfunction in Rats: relationships to dosage and duration of exposure. Pediatr Res. 1988;23(3):275–278.
   PubMed Web of Science ®Google Scholar
• Aluminum in large and small volume parenterals used in total parenteral nutrition–FDA. Proposed rule. Fed Regist. 1998 Jan 5;63(2):176–185.
   PubMedGoogle Scholar
• Poole RL, Hintz SR, Mackenzie NI, et al. Aluminum exposure from pediatric parenteral nutrition: meeting the new FDA regulation. J Parenteral Enteral Nutr. 2008;32(3):242–246.
   PubMed Web of Science ®Google Scholar
• Gaitantzi H, Hakenberg P, Theobald J, et al. Di (2-Ethylhexyl) Phthalate and its role in developing cholestasis. J Pediatr Gastroenterol Nutr. 2018;66(2):e28–e35.
   PubMed Web of Science ®Google Scholar
• Rettberg H, Hannman T, Subotic U, et al. Use of Di(2-Ethylhexyl)Phthalate–containing infusion systems increases the risk for cholestasis. Pediatrics. 2009;124(2):710–716.
   PubMed Web of Science ®Google Scholar
• Hoff DS. Michaelson AS: effects of light exposure on total parenteral nutrition and its implications in the neonatal population. J Pediatr Pharmacol Ther. 2009;14:132–143.
   PubMedGoogle Scholar
• Chessex P, Laborie S, Nasef N, et al. Lavoie JC: shielding parenteral nutrition from light improves survival rate in premature infants. JPEN J Parenter Enteral Nutr. 2017;41:378–383.
   PubMed Web of Science ®Google Scholar
• Shattuck KE, Bhatia J, Grinnell C, et al. The effects of light exposure on the in vitro hepatic response to an amino acid-vitamin solution. JPEN J Parenter Enteral Nutr. 1995;19:398–402.
   PubMed Web of Science ®Google Scholar
• Khashu M, Harrison A, Lalari V, et al. Chessex P: photoprotection of parenteral nutrition enhances advancement of minimal enteral nutrition in preterm infants. Semin Perinatol. 2006;30:139–145.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. PRAC recommendations on signals. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-8-11-july-2019-prac-meeting_en.pdf ( accessed 2020 2 9).
   Google Scholar
• Sondheimer JM, Asturias E. Cadnapaphornchai M: infection and cholestasis in neonates with intestinal resection and long-term parenteral nutrition. J Pediatr Gastroenterol Nutr. 1998;27:131–137.
   PubMed Web of Science ®Google Scholar
• Ross VM, Guenter P, Corrigan ML, et al. Steiger E: central venous catheter infections in home parenteral nutrition patients: outcomes from sustain: American society for parenteral and enteral nutrition’s national patient registry for nutrition care. Am J Infect Control. 2016;44:1462–1468.
   PubMed Web of Science ®Google Scholar
• Ikeda T, Hiromatsu K, Hotokezaka M. Chijiiwa K: up-regulation of intestinal toll-like receptors and cytokines expressions change after TPN administration and a lack of enteral feeding. J Surg Res. 2010;160:244–252.
   PubMed Web of Science ®Google Scholar
• Ormsby JA, Bukoye B, Lajoie D, et al. Enhanced central venous catheter bundle for pediatric parenteral-dependent intestinal failure. Am J Infect Control. 2018;46:1284–1289.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Nasr A, Brindle M. Wales PW: ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: a meta-analysis. Pediatrics. 2012;129:318–329.
   PubMed Web of Science ®Google Scholar
• Rahhal R, Abu-El-Haija MA, Fei L, et al. Systematic review and meta-analysis of the utilization of ethanol locks in pediatric patients with intestinal failure. JPEN J Parenter Enteral Nutr. 2018;42:690–701.
   PubMed Web of Science ®Google Scholar
• Liu H, Liu H, Deng J, et al. Wu Y: preventing catheter-related bacteremia with taurolidine-citrate catheter locks: a systematic review and meta-analysis. Blood Purif. 2014;37:179–187.
   PubMed Web of Science ®Google Scholar
• Clark JE, Graham N, Kleidon T. Ullman A: taurolidine-citrate line locks prevent recurrent central line-associated bloodstream infection in pediatric patients. Pediatr Infect Dis J. 2019;38:e16–e18.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165–178.
   PubMed Web of Science ®Google Scholar
• Fowler VG Jr., Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:695–703.
   PubMed Web of Science ®Google Scholar
• Stanger JD, Oliveira C, Blackmore C, et al. Wales PW: the impact of multi-disciplinary intestinal rehabilitation programs on the outcome of pediatric patients with intestinal failure: a systematic review and meta-analysis. J Pediatr Surg. 2013;48:983–992.
   PubMed Web of Science ®Google Scholar
• Oliveira C, de Silva NT, Stanojevic S, et al. Change of outcomes in pediatric intestinal failure: use of time-series analysis to assess the evolution of an intestinal rehabilitation program. J Am Coll Surg. 2016;222:1180–1188. e1183.
   PubMed Web of Science ®Google Scholar